Arecor Therapeutics PLC APPOINTMENT OF GRANT THORNTON AS AUDITOR (0629K)
27 August 2021 - 10:40PM
UK Regulatory
TIDMAREC
RNS Number : 0629K
Arecor Therapeutics PLC
27 August 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
APPOINTMENT OF GRANT THORNTON AS AUDITOR
Cambridge, UK, 27 August 2021: Arecor Therapeutics plc (AIM:
AREC), a globally focused biopharmaceutical group advancing today's
therapies to enable healthier lives, today announces that Grant
Thornton UK LLP ("Grant Thornton") have been appointed as the
Group's auditor, with immediate effect. Lakin Rose Limited has
resigned as the auditor of Arecor Limited.
The Board's decision to appoint auditors for the Group was made
following a consultation process. Grant Thornton was chosen based
on their public company expertise, reputation and experience. Lakin
Rose has confirmed that it is not aware of any circumstances
connected with its cessation as auditor of Arecor Limited that it
considers should be brought to the attention of the Board,
creditors or shareholders.
In accordance with section 327(c) of the Corporations Act 2001,
a resolution will be tabled at the Company's 2021 Annual General
Meeting to ratify the appointment of Grant Thornton as the Group's
auditor.
The Board of Directors would like to take this opportunity to
thank Lakin Rose UK LLP for their assistance and services to Arecor
Limited.
This announcement contains inside information for the purposes
of the retained UK version of the EU Market Abuse Regulation (EU)
596/2014 ("UK MAR").
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPRMTTMTJTBLB
(END) Dow Jones Newswires
August 27, 2021 08:40 ET (12:40 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2023 to Mar 2024